Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis
NCT ID: NCT01795872
Last Updated: 2015-07-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
278 participants
INTERVENTIONAL
2013-09-30
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
BENEFIT Extension Study
NCT00544037
BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study
NCT00185211
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
NCT03269175
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
NCT00206635
Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.
NCT01031459
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Several diagnostic procedures
Several diagnostic procedures
No drug will be assigned, diagnostic assessment within the study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Several diagnostic procedures
No drug will be assigned, diagnostic assessment within the study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Graz, Styria, Austria
Innsbruck, , Austria
Bruxelles - Brussel, , Belgium
Ghent, , Belgium
Leuven, , Belgium
Liège, , Belgium
Calgary, Alberta, Canada
London, Ontario, Canada
Ottawa, Ontario, Canada
Montreal, Quebec, Canada
Brno, , Czechia
Hradec Králové, , Czechia
Ostrava-Poruba, , Czechia
Prague, , Czechia
Glostrup Municipality, , Denmark
Oulu, , Finland
Seinäjoki, , Finland
Tampere, , Finland
Turku, , Finland
Bordeaux, , France
Clermont-Ferrand, , France
Dijon, , France
Lille, , France
Nice, , France
Rennes, , France
Toulouse, , France
Ulm, Baden-Wurttemberg, Germany
München, Bavaria, Germany
Regensburg, Bavaria, Germany
Würzburg, Bavaria, Germany
Hennigsdorf, Brandenburg, Germany
Giessen, Hesse, Germany
Marburg, Hesse, Germany
Offenbach, Hesse, Germany
Göttingen, Lower Saxony, Germany
Greifswald, Mecklenburg-Vorpommern, Germany
Cologne, North Rhine-Westphalia, Germany
Düsseldorf, North Rhine-Westphalia, Germany
Mainz, Rhineland-Palatinate, Germany
Halle, Saxony-Anhalt, Germany
Erfurt, Thuringia, Germany
Münster, , Germany
Budapest, , Hungary
Budapest, , Hungary
Debrecen, , Hungary
Szeged, , Hungary
Tel Litwinsky, Israel, Israel
Jerusalem, , Israel
Orbassano, Torino, Italy
Gallarate, , Italy
Milan, , Italy
Padua, , Italy
Pavia, , Italy
Torino, , Italy
Sittard, , Netherlands
Bergen, , Norway
Bydgoszcz, , Poland
Krakow, , Poland
Lodz, , Poland
Lublin, , Poland
Wroclaw, , Poland
Coimbra, Coimbra District, Portugal
Ljubljana, , Slovenia
Seville, Andalusia, Spain
Barcelona, Barcelona, Spain
Barcelona, Barcelona, Spain
L'Hospitalet de Llobregat, Barcelona, Spain
Madrid, Madrid, Spain
Málaga, Málaga, Spain
Valencia, Valencia, Spain
Gothenburg, , Sweden
Basel, Canton of Basel-City, Switzerland
Bern, Canton of Bern, Switzerland
Sankt Gallen, Canton of St. Gallen, Switzerland
Sheffield, South Yorkshire, United Kingdom
Aberdeen, , United Kingdom
Dundee, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kappos L, Edan G, Freedman MS, Montalban X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology. 2016 Sep 6;87(10):978-87. doi: 10.1212/WNL.0000000000003078. Epub 2016 Aug 10.
Related Links
Access external resources that provide additional context or updates about the study.
Click here to find information about studies related to Bayer Healthcare products conducted in Europe
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-005262-35
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
16401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.